This designation recognizes Vizient contracted products that improve the healthcare industry.
Danvers, Massachusetts, January 11, 2024–(BUSINESS WIRE)–Neurologica Corporation announces that its Omnitom Elite PCD has received Breakthrough Technology designation from Vizient, the nation’s largest provider-led healthcare performance improvement company . NeuroLogica Corp. exhibited the OmniTom Elite PCD at the Vizient Innovative Technology Exchange in Dallas on October 17th.
Healthcare professionals who participate in Vizient’s customer-led councils will explore carefully selected products and their potential to enhance clinical care, patient safety, provider safety, and improve healthcare organization operations. We review technology annually. Innovative technology designations are given to previously contracted products to communicate to healthcare providers the impact of these innovations on patient care and the healthcare organization’s business model.
NeuroLogica’s OmniTom Elite PCD is a breakthrough innovation in medical imaging. This mobile CT scanner has high-resolution imaging and material resolution capabilities that allow medical professionals to perform precise neurological examinations at a patient’s bedside in her ICU or in another area designated by the facility, such as the ER department. You can now perform imaging. Cleared for use in adults, reduced artifacts improve the ability to identify bleeding along the skull compared to contrast agents, reduce the risk of potential misdiagnosis, and better identify posterior fossa pathology. It will help you identify it properly. After thrombectomy, blood and iodine staining can be distinguished without waiting. Whether traditional CT PCD, dual energy, or spectral CT imaging is used, the NeuroLogica OmniTom PCD scanner helps standardize the entire imaging system.
“Neurologica has always been committed to innovating and expanding the world of healthcare,” said Renaud Maroberti, head of mCT business. “From the development of mobile CT to the implementation of the first single-source, single-detector photon-counting CT, we are witnessing the next stage in image processing and standardization.”
said Kelly Flaharty, senior director of contract services at Vizient. “A customer-led council determined that the OmniTom Elite PCD deserves this designation because of its potential to further transform healthcare.”
Vizient represents a diverse customer base that includes academic medical centers, pediatric facilities, community hospitals, integrated care delivery networks, and non-acute care providers, with annual purchasing volume of approximately $130 billion. Through our Innovative Technology Program, Vizient works with customer-led councils and task forces to evaluate products that have the potential to bring true innovation to healthcare. Vizient may award contracts outside of the competitive bidding cycle to products deemed worthy of innovative technology designation.
About Neurologica Inc.
NeuroLogica Corp. is a healthcare subsidiary of Samsung Electronics Co., Ltd. that develops, manufactures, and sells innovative imaging technologies to provide healthcare providers with fast, easy, and accurate diagnostic solutions. I am committed to doing so. NeuroLogica is a global headquarters and manufacturer of mobile computed tomography equipment. NeuroLogica’s growing portfolio of advanced medical technologies is used by leading healthcare organizations around the world to help healthcare providers enhance patient care, improve patient satisfaction, and improve workflow efficiency. It’s helping me improve. See below for more information. www.NeuroLogica.com. The OmniTom Elite PCD is not currently US FDA 510(k) cleared for neonatal or pediatric scanning and may not be commercially available in all countries. Sales and shipments will be effective only after regulatory team approval. Please contact your local sales representative for more information. This product is a medical device. Please read the user manual carefully before use.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240111828667/en/
contact address
Media inquiries
Jen Lunch
boston imaging
860.620.7732
jlanci@bostonimaging.com
Kang Dae Jin
IR, Samsung Medicine
daejin@samsungmedison.com
